The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05630573
Recruitment Status : Recruiting
First Posted : November 29, 2022
Last Update Posted : November 29, 2022
Sponsor:
Information provided by (Responsible Party):
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

The purpose of this clinical trial is to evaluate the safety, tolerability and pharmacokinetics (PK) profile of TNM001 injection in healthy preterm and term infants. The main questions it aims to answer are:

  • the safety and tolerability of TNM001 injection
  • the pharmacokinetic (PK) profile of TNM001

Condition or disease Intervention/treatment Phase
Respiratory Syncytial Virus Infections Biological: TNM001 Biological: Placebo Phase 1 Phase 2

Detailed Description:
This phase Ib/IIa study is designed to assess the safety, tolerability, and pharmacokinetics (PK) profile TNM001 in healthy preterm and term infants. This study will also compare the incidence of RSV infection between different doses of TNM001 and placebo, which will be used to select the dose to be studied in the later phase of clinical trials of TNM001. Approximately 30 subjects will be randomized and will be dosed once on Day 1 and followed up until Day 151. Around 6 investigational study centres participate in the study.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase Ib/IIa Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TNM001 Injection in Chinese Healthy Preterm and Term Infants
Actual Study Start Date : October 25, 2022
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: TNM001 Injection dose 1 or placebo
low dose administered
 Biological: TNM001
intramuscular injection

Biological: Placebo
intramuscular injection
Experimental: TNM001 Injection dose 2 or placebo
medium dose administered
 Biological: TNM001
intramuscular injection

Biological: Placebo
intramuscular injection
Experimental: TNM001 Injection dose 3 or placebo
high dose administered
 Biological: TNM001
intramuscular injection

Biological: Placebo
intramuscular injection


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and tolerability of TNM001 Injection [ Time Frame: 150 days post dose ]
    Type and incidence of adverse events and serious adverse events


Secondary Outcome Measures :
  1. Area Under the Concentration-Time Curve From Zero to Infinity (AUC [0-infinity]) of TNM001 [ Time Frame: 150 days post dose ]
    The pharmacokinetic (PK) parameter AUC (0-infinity) will be estimated based on the serum concentrations of TNM001

  2. Maximum Observed Serum Concentration (Cmax) of TNM001 [ Time Frame: 150 days post dose ]
    The Cmax is the maximum observed serum concentration of TNM001

  3. Terminal Elimination Half Life (t1/2) of TNM001 [ Time Frame: 150 days post dose ]
    Terminal phase elimination half-life (t1/2) is the time required for half of the drug to be eliminated from the serum

  4. Serum anti-RSV neutralizing antibodies titer levels in each dose cohort [ Time Frame: 150 days post dose ]
    To summarize the proportion of subjects with severalfold increase after dosing compared to the predose (baseline)

  5. Anti-drug antibody (ADA) positive rate of TNM001 [ Time Frame: 150 days post dose ]
    The evaluation indicator of immunogenicity is the ADA positive rate in subjects


Other Outcome Measures:
  1. Lower respiratory tract infection(LRTI) [ Time Frame: 150 days post dose ]
    The incidence of LRTI


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  1. Healthy preterm infants and term infants within 1 year old of age
  2. Infants who are in the first RSV infection season at the time of randomization

Key Exclusion Criteria:

  1. Any fever or acute illness within 7 days prior to dosing
  2. LRTI prior to randomization
  3. Received any anti-RSV monoclonal antibody or RSV vaccine
  4. Any other circumstances that, in the opinion of the investigator, may interfere with the assessment of the study drug or the interpretation of the study results
  5. The subject is a child of the investigator or his/her subordinate study personnel or relatives or sponsor staff
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05630573


Contacts
Layout table for location contacts
Contact: Ying Wang +86 0756 7263999 emma.wang@trinomab.com
Contact: Xiaoyan Wen +86 0756 7263999 xiaoyan.wen@trinomab.com

Locations
Layout table for location information
China, Hebei
The Second Hospital of Hebei Medical University Recruiting
Shijiazhuang, Hebei, China, 050000
Contact: Zhiqing Zhang    +86 15803210627    777yyy@sina.cn   
China, Hunan
Hunan Provincial People's Hospital Not yet recruiting
Changsha, Hunan, China, 410005
Contact: Shengdan Nie    +86 18673126823    792139029@qq.com   
Contact: Aimin Zhang    +86 13873140648    Lilly610@sina.com   
The Third Xiangya Hospital of Central South University Not yet recruiting
Changsha, Hunan, China, 410006
Contact: Guoping Yang    +86 13974817168    ygp9880@163.com   
Contact: Minghua Yang    +86 13973135843    yamahua123@163.com   
China, Shanxi
Linfen People's Hospital Not yet recruiting
Linfen, Shanxi, China, 041000
Contact: Zhendong Wang    +86 15835736958    Lfsrmyygcp@163.com   
Contact: Jiangchuan Zhu    +86 13303576606    Lfsrmyygcp@163.com   
Yuncheng Central Hospital Not yet recruiting
Yuncheng, Shanxi, China, 044099
Contact: Fengli Zhao    +86 18235960066    zhaoflhh@163.com   
China, Sichuan
West China Second University Hospital, Sichuan University Recruiting
Chengdu, Sichuan, China, 610041
Contact: Hanmin Liu    +86 18180609009    Hanmin@via.163.com   
Contact: Qin Yu    +86 18180603576    908929936@qq.com   
Sponsors and Collaborators
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Hanmin Liu West China Second Hospital, Sichuan University
Principal Investigator: Qin Yu West China Second Hospital, Sichuan University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Zhuhai Trinomab Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier: NCT05630573    
Other Study ID Numbers: TNM001-201
First Posted: November 29, 2022    Key Record Dates
Last Update Posted: November 29, 2022
Last Verified: November 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Syncytial Virus Infections
Virus Diseases
Infections
Pneumovirus Infections
 Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections